About
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.
Current Value
$9.351 Year Return
Current Value
$9.351 Year Return
Key Details
Market Cap
$397.37M
P/E Ratio
-9.65
1Y Stock Return
53.44%
1Y Revenue Growth
-12.56%
Dividend Yield
0.00%
Price to Book
2.2
Strategies that include ANGO
Double maintains 1 strategies that include ANGO - AngioDynamics, Inc.
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Stock's related to ANGO
The stocks that are correlated to ANGO - AngioDynamics, Inc. are SANA, VIR, ACCD, MATW, TWI
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 56.58% | $308.28M | -83.90% | 0.00% | |
| 54.52% | $817.37M | -37.06% | 0.00% | |
A ACCDAccolade, Inc. | 50.91% | $574.77M | -24.22% | 0.00% |
| 40.91% | $638.57M | -26.93% | 4.86% | |
| 38.94% | $441.12M | -43.62% | 0.00% | |
C CYRXCryoPort, Inc. | 38.36% | $271.51M | -70.69% | 0.00% |
| 37.61% | $2.93B | +59.46% | 0.00% | |
A ACVAACV Auctions, Inc. | 36.07% | $2.29B | -25.94% | 0.00% |
| 36.05% | $283.97M | -38.11% | 0.00% | |
| 35.75% | $496.11M | -11.22% | 2.03% | |
H HUBGHub Group, Inc. | 34.06% | $2.09B | -18.69% | 1.53% |
P PHRPhreesia, Inc. | 34.03% | $1.46B | +11.59% | 0.00% |
E EBAYeBay, Inc. | 34.01% | $30.92B | +29.11% | 1.69% |
| 33.44% | $1.57B | -33.22% | 0.00% | |
E ENOVEnovis Corp. | 33.31% | $1.92B | -43.41% | 0.00% |
| 33.24% | $290.67M | -37.93% | 0.00% | |
P PXP10, Inc. | 32.89% | $1.17B | +25.36% | 1.39% |
K KFRCKforce, Inc. | 32.72% | $902.81M | -30.52% | 3.31% |
| 32.30% | $974.75M | -77.70% | 0.00% | |
| 32.21% | $1.81B | +24.71% | 2.32% | |
ETF's related to ANGO
The ETFs that are correlated to ANGO - AngioDynamics, Inc. are CPRJ, XHE, RSPA, GNOM, PRFZ
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 46.30% | $48.65M | 0.69% | |
| 41.81% | $176.51M | 0.35% | |
| 40.27% | $294.73M | 0% | |
| 35.17% | $48.48M | 0.5% | |
| 34.64% | $2.38B | 0.39% | |
| 34.33% | $163.92M | 0.35% | |
| 34.30% | $2.79B | 0.07% | |
| 34.09% | $5.18B | 0.59% | |
| 33.97% | $11.17B | 0.03% | |
| 33.90% | $1.24B | 0.1% | |
| 33.88% | $11.04B | 0.24% | |
| 33.80% | $521.56M | 0.2% | |
| 33.70% | $79.87B | 0.06% | |
| 33.68% | $1.41B | 0.47% | |
| 33.63% | $6.49B | 0.18% | |
| 33.53% | $184.53M | 0.52% | |
| 33.40% | $4.63B | 0.4% | |
| 33.31% | $4.26B | 0.31% | |
| 33.30% | $842.66M | 0.6% | |
| 33.26% | $964.24M | 0.62% | |
News
Yahoo
ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.
Yahoo
AngioDynamics Inc (ANGO) reports a robust 9% revenue growth, driven by significant gains in MedTech and mechanical thrombectomy segments, while navigating challenges in reimbursement and cash flow.
Yahoo
Q3 2025 AngioDynamics Inc Earnings Call
Yahoo
AngioDynamics (ANGO) delivered earnings and revenue surprises of 123.08% and 2%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
LATHAM, N.Y. (AP) — AngioDynamics Inc. ANGO) on Wednesday reported a loss of $4.4 million in its fiscal third quarter. On a per-share basis, the Latham, New York-based company said it had a loss of 11 cents.
Yahoo
LATHAM, N.Y., April 02, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds